Abstract 271P
Background
Immune checkpoint inhibitors are now considered revolutionary agents in the treatment of various cancers in the upfront and metastatic setting. The low toxicity and improved quality of life seen with these drugs are an added advantage. However, the real world data regarding their toxicities is limited. The currently published Indian data are restricted to isolated case reports. We planned this study of addressing toxicity profile of various Immunotherapy agents among Indian patients.
Methods
This prospective study was conducted at a tertiary care Hospital in Delhi from Aug 2019 till Nov 2021 after ethics approval. All patients included were treated with Nivolumab, Pembrolizumab, Atezolizumab and Durvalumab. All lines of therapy were allowed for enrolment. Immune Related adverse events were recorded for individual agents and therapy continued until progression or unacceptable toxicity. Toxicities were graded according to NCI:CTCAE criteria ver 4.0. Statistical analysis was done with the use of SPSS software ver 21.0.
Results
A total of 53 patients received Nivolumab, Pembrolizumab, Atezolizumab and Durvalumab. Majority of patients were less than 60 years of age (64.15%). ECOG PS was 1 in 66.04% and PS 2 in 32.08%. Carcinoma(Ca) Lung was the most frequent malignancy (n=18) followed by renal cell carcinoma (15.09%), Relapsed/Refractory Hodgkin’s Lymphoma ( 15.09%), Ca Urinary Bladder ( 11.32%), Malignant Melanoma (7.55%), Recurrent /Metastatic Head and neck cancer ( 7.55%), one each patient of Hepatocellular Ca, Ca Oesophagus, Stomach, Endometrium and Rectum.Nivolumab was used in the majority of study population (49.06%) followed by Pembrolizumab (37.74%), Atezolizumab (9.43%) and Durvalumab (3.77%). Majority of agents were used in 2nd line (52.83%) across various malignancies followed by 1st line usage in 22.64%, 3rd line in 11.32%, 4th line in 7.55% and 5th line usage in 5.66%. All grade adverse events were fatigue (73.58%), anaemia (62.26%), pneumonitis (16.98%), rash (11.32%), dyspnoea (9.43%), diarrhoea (9.43%) and hypothyroidism (7.55%) in majority of patients. Hyperglycaemia, pleural effusion, arthritis, arthralgia and infusion reaction comprising 1.89% each. Severe Grade 3 anaemia was seen in 1 patient (1.89%). None of these led to treatment discontinuation. Details of toxicities are depicted in the table. Table: 271P
Distribution of adverse events in total and in each drugs
Variables | Frequency | Percentage | Atezolizumab | Durvalumab | Nivolumab | Pembrolizumab | |
Dermatologic | Rash | 6 | 11.32% | 0 | 0 | 3 | 3 |
Grade (Gd) 1 | 4 | 7.55% | 0 | 0 | 2 | 2 | |
Gd 2 | 2 | 3.77% | 0 | 0 | 1 | 1 | |
Gastroenterology | Diarrhoea | 5 | 9.43% | 1 | 0 | 2 | 2 |
Gd 1 | 4 | 7.55% | 1 | 0 | 1 | 2 | |
Gd 3 | 1 | 1.89% | 0 | 0 | 1 | 0 | |
Endocrine | Hyperglycaemia | 1 | 1.89% | 0 | 1 | 0 | 0 |
Gd 2 | 1 | 1.89% | 0 | 1 | 0 | 0 | |
Hypothyroidism | 4 | 7.55% | 1 | 0 | 1 | 2 | |
Gd 2 | 4 | 7.55% | 1 | 0 | 1 | 2 | |
Respiratory | Dyspnoea | 5 | 9.43% | 1 | 0 | 2 | 2 |
Gd 1 | 5 | 9.43% | 1 | 0 | 2 | 2 | |
Pneumonitis | 9 | 16.98% | 0 | 0 | 4 | 5 | |
Gd 1 | 8 | 15.09% | 0 | 0 | 4 | 4 | |
Gd 2 | 1 | 1.89% | 0 | 0 | 0 | 1 | |
Pleural effusion | 1 | 1.89% | 0 | 0 | 0 | 1 | |
Gd 2 | 1 | 1.89% | 0 | 0 | 0 | 1 | |
Hematologic | Anaemia | 33 | 62.26% | 3 | 1 | 17 | 12 |
Gd 1 | 31 | 58.49% | 3 | 1 | 17 | 10 | |
Gd 2 | 1 | 1.89% | 0 | 0 | 0 | 1 | |
Gd 3 | 1 | 1.89% | 0 | 0 | 0 | 1 | |
Infusion related | Gd 1 | 1 | 1.89% | 0 | 0 | 0 | 1 |
General | Fatigue | 39 | 73.58% | 5 | 1 | 17 | 16 |
Gd 1 | 37 | 69.81% | 5 | 1 | 16 | 15 | |
Gd 2 | 2 | 3.77% | 0 | 0 | 1 | 1 |
Conclusions
Overall, the toxicity seen in Indian patients largely comparable with international experiences and Oncologists should feel reassured using these agents in similar settings in India.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
186P - Degradation of BRCA2 expression by hyperthermia sensitizes HRD-negative (BRCA2 wild-type) ovarian cancer cells to niraparib
Presenter: Junyang Li
Session: Poster viewing 03
187P - BUB1 (2530C>T) polymorphism and expression affects chemotherapy response and predicts poor prognosis in advanced epithelial ovarian cancer
Presenter: Sinjini Sarkar
Session: Poster viewing 03
188P - Spatial transcriptomic analysis of tumor tissue in ovarian cancer patients treated with neoadjuvant chemotherapy
Presenter: Irina Larionova
Session: Poster viewing 03
189P - LncRNA NKILA as a negative regulator of NFkB in ascites in ovarian cancer
Presenter: Dinara Dolgova
Session: Poster viewing 03
190P - Real-world applications of poly (ADP-ribose) polymerase inhibitors for ovarian cancer: A single-center study in China
Presenter: dengfeng wang
Session: Poster viewing 03
191P - Phase II study of sodium valproate in combination with oral etoposide in platinum-resistant ovarian cancer
Presenter: N Thejeswar
Session: Poster viewing 03
192P - Human epididymis protein 4 as a predictor of response to neoadjuvant chemotherapy in epithelial ovarian cancer
Presenter: Sarada Planjery
Session: Poster viewing 03
193P - Experience with olaparib in the treatment of BRCA-associated tumors in real clinical practice: Experience of re-challenge mode of olaparib usage
Presenter: Alexander Sultanbaev
Session: Poster viewing 03
194P - A study of the treatment response of concomitant external beam radiotherapy (EBRT) and intracavitary brachytherapy in the management of locally advanced carcinoma of uterine cervix
Presenter: Asish Chowdhury
Session: Poster viewing 03
195P - Awareness of human papillomavirus (HPV) infection, cervical cancer (CC), and vaccine among females in Sultanate of Oman
Presenter: Abdulrahman Al-Mirza
Session: Poster viewing 03